Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2300 participants.
Also called NCT05380063
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,300 participants
- Registry
-
NCT05380063
-
- Other papers using this trial's data
- Efficacy of dual antiplatelet therapy for three months versus 12 months after coronary artery bypass grafting: multicentre, double blinded, randomised controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05380063. Randomized; quadruple masking; primary purpose treatment. Start 2023-02-14 (actual); primary completion 2025-07-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting
- Acronym
- TOP-CABG
- Condition
- Coronary Artery Disease
- Condition
- Coronary Artery Bypass Grafting
- Condition
- Dual Antiplatelet Therapy
- Condition
- Bleeding
- Condition
- Myocardial Infarction
- Condition
- Myocardial Ischemia
- Condition
- Angina Pectoris
- Intervention (Drug)
- De-escalated Dual Antiplatelet Therapy
- Intervention (Drug)
- Dual Antiplatelet Therapy
- Lead sponsor
- China National Center for Cardiovascular Diseases
Record details
- Record id
cardio:ct-nct05380063- Content hash
0ba01d0f53465f01080fe724d161bd47bd56b3e968c46fe75c05490308908ecc